WO2020248742A1 - 一种组合物 - Google Patents

一种组合物 Download PDF

Info

Publication number
WO2020248742A1
WO2020248742A1 PCT/CN2020/088646 CN2020088646W WO2020248742A1 WO 2020248742 A1 WO2020248742 A1 WO 2020248742A1 CN 2020088646 W CN2020088646 W CN 2020088646W WO 2020248742 A1 WO2020248742 A1 WO 2020248742A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
small intestine
bioavailability
chitosan
test
Prior art date
Application number
PCT/CN2020/088646
Other languages
English (en)
French (fr)
Inventor
张菁
金文波
Original Assignee
张菁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 张菁 filed Critical 张菁
Priority to US17/282,833 priority Critical patent/US12036197B2/en
Priority to EP20822549.0A priority patent/EP3871694A4/en
Publication of WO2020248742A1 publication Critical patent/WO2020248742A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention belongs to the technical field of biomedicine, and specifically relates to a composition containing a surfactant, an acrylic polymer, chitin and its derivatives, and a metal ion chelating agent.
  • the oral drug technology has always been a hot research topic. This technology involves taking drugs that can only be injected subcutaneously or intravenously through oral enteric-coated capsules to reach the small intestine and then disintegrate, and are absorbed through the small intestine to reach the blood circulatory system with the assistance of different combinations of preparations.
  • oral drugs Compared with subcutaneous or intravenous drugs, oral drugs have two advantages: for patients, self-administration, higher drug acceptance, and lower risk of infection; for drug manufacturers, oral drugs It is more tolerant to workshop level requirements and lower production costs.
  • the influencing factors include the relative molecular mass, spatial structure and hydrophobicity of the drug itself, as well as various barriers in the body (such as acid barrier, enzyme barrier and Membrane barrier).
  • the first-pass effect after the drug enters the portal venous system through the gastrointestinal tract and enters the liver is also a problem that must be faced in oral drug administration.
  • the strategies to improve the absorption of oral drugs mainly include chemical modification, addition of absorption enhancers, addition of enzyme inhibitors, nanocarriers, liposome carriers, and microemulsion carriers.
  • the applicant obtained a new composition after many creative researches, which is prepared from surfactants, acrylic polymers, chitin and its derivatives, and metal ion chelating agents.
  • the composition of the present invention can be prepared into a composite adjuvant, which can improve the absorption of the active ingredient in the small intestine after being combined with the active ingredient of the medicine.
  • the composition of the present invention is an organic whole, and through a synergistic effect, it ensures the absorption of the medicine (active ingredient or active ingredient) in the intestine.
  • the present invention is achieved through the following technical solutions.
  • a composition comprising: a surfactant, an acrylic polymer, chitin and its derivatives, and a metal ion chelating agent.
  • a pharmaceutical composition containing: a surfactant, an acrylic polymer, chitin and its derivatives, and a metal ion chelating agent.
  • the surfactant is one or more of anionic surfactants or nonionic surfactants.
  • the acrylic polymer is one or more of carbomer, carbomer 910, acrylic carbomer 934, and carbomer 934P.
  • chitin and its derivatives are chitin, chitosan, carboxymethyl chitosan, acylated chitosan, alkylated chitosan, hydroxylated chitosan, chitosan quaternary ammonium salt, One or more of chitosan oligosaccharide and chitosan sulfate.
  • the metal ion chelating agent is citric acid or its salt, tartaric acid or its salt, malic acid or its salt, maleic acid or its salt, gluconic acid or its salt, ethylenediaminetetraacetic acid or One or more of its salt, aminotriacetic acid or its salt, diethylenetriaminepentaacetic acid or its salt.
  • the preferred composition is: the surfactant is sodium lauryl sulfate, the acrylic polymer is carbomer, the chitin and its derivatives are chitosan, and the metal ion chelating agent is sodium citrate.
  • composition is used to ensure the absorption of drugs (active ingredients or active ingredients) in the small intestine.
  • composition is used to promote the absorption of drugs (active ingredients or active ingredients) in the small intestine.
  • the weight ratio of the surfactant, acrylic polymer, chitin and its derivatives to the metal ion chelating agent is 15-25:5-8:5-8:50-80.
  • the weight ratio of the surfactant, acrylic polymer, chitin and its derivatives to the metal ion chelating agent is 19-21:6-7:6-7:60-70.
  • the drugs include, but are not limited to, polypeptides.
  • Polypeptides include Exenatide, Nesiritide, Gonadorelin, Leuprolide, Glucagon recombinant, Oxytocin, Bivalirudin, Sermorelin, Gramicidin D, Insulin recombinant, Vasopressin, Cosyntropin, Octreotide, Vapreotide, Metroraditide, GH, etc.Pericasin, Actypacin, Actypacin, alpha, etc.
  • the drugs include, but are not limited to, insulin and its analogs.
  • the drugs include, but are not limited to, growth hormone and its analogs.
  • a composition for promoting intestinal absorption which is prepared from raw materials containing surfactants, acrylic polymers, chitin and its derivatives, and metal ion chelating agents.
  • composition for promoting intestinal absorption as described above is prepared as an auxiliary material, and the auxiliary material is used as an oral preparation auxiliary material.
  • the adjuvant can be used for: medicines (active ingredients or active ingredients) that cannot be taken orally and can only be injected can be administered orally, thereby changing the medicines (active ingredients or active ingredients) The way of administration.
  • composition of the present invention can ensure the absorption in the intestine of drugs (active ingredients or active ingredients) that are easily decomposed in the gastrointestinal tract.
  • composition of the present invention can promote the intestinal absorption of drugs (active ingredients or active ingredients) that are not easily absorbed in the gastrointestinal tract.
  • composition of the present invention promotes absorption in the small intestine and requires release in the small intestine to exert its effect
  • rodents use small intestinal catheters for administration and mammals use enteric-coated capsules for oral administration during drug efficacy and pharmacokinetic tests. .
  • composition and the polypeptides listed above are matched one by one on rodents for bioavailability testing, and at the same time, some polypeptides are selected for pharmacodynamic and pharmacokinetic testing on different animals.
  • Figure 1 shows the PD test of Exenatide on STZ rats
  • the abscissa is time (h), and the ordinate is the blood sugar reduction efficiency (%);
  • the solid round solid line is the small intestine injection of normal saline 2ml/kg
  • the solid square dashed line is the subcutaneous injection of Exenatide 1 ⁇ g/kg
  • the solid round dashed line is the subcutaneous injection of Exenatide 250 ⁇ g/kg
  • the solid triangle dashed line is the subcutaneous injection of Exenatide 1mg/kg
  • the hollow triangle solid line is the small intestine administration of Test Example 1 composition + Exenatide (administration amount Exenatide 30 ⁇ g/kg)
  • the hollow round solid line is the small intestine administration of Test Example 1 composition + Exenatide (administration amount Exenatide 40 ⁇ g/kg)
  • hollow The solid square line is the small intestine administration of Test Example 1 composition + Exenatide (administration amount Exenatide 50 ⁇ g/kg)
  • the hollow solid line is the small intestine administration of Test Example 1 composition + Exenatide (administration amount Exenatide 60 ⁇ g/kg).
  • Figure 2 shows the iv PK test of Exenatide in rats
  • the abscissa is time (min), and the ordinate is the concentration of Exenatide in rat plasma (ng/ml).
  • Figure 3 shows the ei PK test of the Exenatide/Test Example 1 composition in rats
  • the abscissa is time (min), and the ordinate is the concentration of Exenatide in rat plasma (ng/ml).
  • Figure 4 shows the iv PK test of Exenatide on beagle dogs
  • the abscissa is time (min), and the ordinate is the Exenatide concentration (ng/ml) in beagle plasma.
  • Figure 5 shows the po PK test of Exenatide/Test Example 1 composition on beagle dogs
  • the abscissa is time (min), and the ordinate is the Exenatide concentration (ng/ml) in beagle plasma.
  • Figure 6 shows the PD test of Exenatide on Alloxan Beagle dogs
  • the abscissa is time (h), and the ordinate is beagle blood glucose (mM);
  • the solid round solid line is the postprandial blood glucose status of Alloxan beagle dogs
  • the solid square solid line is the postprandial blood glucose status of Alloxan beagle dogs swallowing Exenatide/Test Example 1 composition
  • the solid diamond-shaped solid line is normal beagle dogs. Serum conditions after meals.
  • the following experiments of the present invention are conclusive experiments by research and development personnel based on the technical solutions to be protected by the present invention on the basis of multiple creative experiments.
  • the quantitative tests in the following test examples are all set to three repeated experiments, and the data is the average value of the three repeated experiments or the average ⁇ standard deviation.
  • Test Example 1 Significantly improve the efficacy of Exenatide (Exendin4, EXE4) administered into the small intestine
  • the composition is: the surfactant is sodium lauryl sulfate, the acrylic polymer is carbomer, chitin and its derivatives are chitosan, the metal ion chelating agent is sodium citrate, and the weight ratio is: 20 :6.5:6.5:65.
  • Test animals SD male rats, intraperitoneally injected 45mg/kg STZ to construct a hyperglycemia model;
  • Small intestine efficacy test subcutaneous injection (sc) or administration through small intestine catheter (ei), blood samples were collected at 0h, 3h, 6h and 9h to detect blood glucose.
  • Test Example 2 Significantly improve the bioavailability of Exenatide administered in the small intestine
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of Exenatide is 200 ⁇ g/kg and the dose of Exenatide is 200 ⁇ g/kg on adult SD rats in fasting state.
  • the Exenatide of the composition of Example 1 was 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C3000rpm for 5min, and the plasma was collected and snap frozen.
  • ELISA detection method Coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and incubated with a blood sample or standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test animal adult male beagle.
  • Oral PK test Animals are in fasting state. After oral administration of enteric-coated capsules, blood samples are collected at 0.5, 1, 1.5, 2, 2.5, and 3 hours. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 0.3 ⁇ g/kg Exenatide, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen. See Figure 4 and Figure 5.
  • ELISA detection method Coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and incubated with a blood sample or standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • the PK data of beagle dogs showed that the AUC of intravenous injection of 0.3 ⁇ g/kg of Exenatide was about 0.82 ng/ml.hour, and the AUC of oral Exenatide/Test Example 1 composition 0.7 mg was about 1.36 ng/ml.hour.
  • the bioavailability of the Oral Exenatide/Test Example 1 composition is about 0.83%.
  • Exenatide cannot successfully enter the blood without the assistance of the composition of the present invention, but after adding the composition of the present invention, the blood entry efficiency is significantly improved. Although the blood efficiency of Exenatide increased slightly with the increase in the weight of the composition of Test Example 1, the increase was limited. Considering the convenience of oral administration and the effectiveness of drugs, the amount of No. 3 capsules is more appropriate.
  • Test Example 4 The composition of Exenatide/Test Example 1 can significantly inhibit the increase in blood glucose of Alloxan Beagle dogs after meals
  • Animal physical examination and adaptation Collect fasting blood samples of animals to test blood biochemical indicators. After confirming that everything is normal, place the animals in a quieter room to adapt for 1 week. The daily feeding time and feeding amount are required to be consistent;
  • Blood samples are collected at 4 time points every day (before feeding, 2h, 4h, 6h after feeding) for 5 consecutive days;
  • Modeling test fasting state, intravenous injection of 60mg/kg Alloxan solution, one week later, blood samples are collected at 4 time points every day (before feeding, 2h, 4h, 6h after feeding) for 5 consecutive days; judge according to the collected data Whether the model is qualified. Start the efficacy test if qualified;
  • Efficacy test swallow the test capsule before feeding, and collect blood samples at 4 time points (before feeding, 2h, 4h, 6h after feeding).
  • Test Example 5 The composition of the present invention significantly improves the bioavailability of Nesiritide administered in the small intestine
  • composition of the present invention Tween 80, carbomer 910, carboxymethyl chitosan and sodium tartrate is 3:1:1:10.
  • Nesiritide and the above composition at a weight ratio of 1:5 thoroughly, and set aside;
  • Test animals adult male SD rats;
  • Nesiritide 200 ⁇ g/kg On adult SD rats in fasting state, the dose of Nesiritide is 200 ⁇ g/kg in a small intestine catheter at a volume of 1ml/kg and the above composition is added to the small intestine catheter (ei) Nesiritide 200 ⁇ g/kg, after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Nesiritide 200 ⁇ g/kg after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Nesiritide, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • ELISA detection method Coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and incubated with a blood sample or standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Nesiritide was administered 200 ⁇ g/kg through the small intestine, and the blood concentration was lower than the lower limit of ELISA detection. After adding the above composition, the bioavailability of intestinal administration can reach 1.22%.
  • Test Example 6 Significantly improve the bioavailability of Gonadorelin administered into the small intestine
  • the weight ratio of the composition of the present invention is 17:6:6.5:55.
  • Test animals adult male SD rats;
  • Gonadorelin 200 ⁇ g/kg On adult SD rats in fasting state, the dose of Gonadorelin is 200 ⁇ g/kg and the combination of the invention is added to the small intestine catheter injection (ei) with the administration volume of 1ml/kg via the small intestine catheter.
  • Gonadorelin 200 ⁇ g/kg after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Gonadorelin, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 7 The composition of the present invention can significantly improve the bioavailability of Leuprolide administered to the small intestine
  • composition of the present invention is: polyethylene glycol 4000, carbomer, chitosan oligosaccharide, and citric acid in a weight ratio of 19:6:6:60.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of Leuprolide is 200 ⁇ g/kg by a small intestine catheter at a dose of 1ml/kg, and a separate group, small intestine catheter injection (ei) with the combination of the present invention Leuprolide 200 ⁇ g/kg, after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Leuprolide, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • ELISA detection method Coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and incubated with a blood sample or standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 8 The composition of the present invention can significantly improve the bioavailability of Teduglutide administered in the small intestine
  • the weight ratio of the composition of the present invention is 25:8:8:80.
  • Teduglutide and the composition of the present invention are thoroughly mixed according to a weight ratio of 1:5, and set aside;
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of Teduglutide is 200 ⁇ g/kg in a small intestine catheter at a volume of 1ml/kg, and the group is divided into small intestine catheter injection (ei) with the combination of the present invention Teduglutide 200 ⁇ g/kg, after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Teduglutide, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 9 The composition of the present invention can significantly improve the bioavailability of Oxytocin administered in the small intestine
  • composition of the invention is: sodium lauryl sulfate, carbomer 934, water-soluble chitosan, and disodium edetate in a weight ratio of 24:7.5:7:75.
  • Test animals adult male SD rats;
  • Oxytocin 200 ⁇ g/kg On adult SD rats in fasting state, the dose of Oxytocin is 200 ⁇ g/kg and the dose of Oxytocin is 200 ⁇ g/kg in the adult SD rats in the fasting state.
  • Oxytocin 200 ⁇ g/kg after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Oxytocin, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 10 The composition of the present invention can significantly improve the bioavailability of bivalirudin administered to the small intestine
  • composition of the present invention is: sodium lauryl sulfate, carbomer, chitosan, and citric acid in a weight ratio of 19:6.5:7:67.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, 1ml/kg was administered via a small intestinal catheter at a dose of 1ml/kg, so that the dose of Bivalirudin was 200 ⁇ g/kg, divided into another group, small intestinal catheter injection (ei) added the combination of the present invention Bivalirudin 200 ⁇ g/kg, after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Bivalirudin, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 11 The composition of the present invention can significantly improve the bioavailability of Sermorelin (Sermorelin) in the small intestine
  • the weight ratio of the composition of the present invention is 3:1:1:10.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of Sermorelin is 200 ⁇ g/kg and the dose of Sermorelin is 200 ⁇ g/kg in adult SD rats in fasting state. Sermorelin 200 ⁇ g/kg, after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Sermorelin, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 12 The composition of the present invention can significantly improve the bioavailability of Gramicidin D (Gramicidin) administered into the small intestine
  • composition of the present invention the weight ratio of sodium lauryl sulfate, carbomer, chitosan, and sodium citrate is 19:6:6:60.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of Gramicidin is 200 ⁇ g/kg and the dosage of Gramicidin is 200 ⁇ g/kg, and the combination of the invention is added to the small intestine catheter injection (ei) Gramicidin 200 ⁇ g/kg, after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Gramicidin 200 ⁇ g/kg after administration 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg Gramicidin, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 13 The composition of the present invention can significantly improve the bioavailability of recombinant insulin (rInsulin) administered into the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:68.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, administer 1ml/kg via a small intestinal catheter to make the dose of rInsulin 200 ⁇ g/kg.
  • small intestinal catheter injection adds the combination of the present invention
  • the rInsulin of the substance was 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg rInsulin, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 14 The composition of the present invention can significantly improve the bioavailability of Vasopressin administered in the small intestine
  • composition of the present invention the weight ratio of sodium lauryl sulfate, carbomer, chitosan, and sodium citrate is 23:8:7.5:80.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the administration volume is 1ml/kg through small intestinal catheter, so that the dose of vasopressin is 200 ⁇ g/kg, another group, small intestinal catheter injection (ei) add this
  • the vasopressin of the inventive composition was 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and plasma was collected Quick freezing.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg vasopressin, blood samples were collected at 5, 15, 30, 60, 90, 120 min. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • vasopressin was administered 200 ⁇ g/kg through the small intestine, and the blood concentration was lower than the lower limit of ELISA detection. After adding the composition of the present invention, the bioavailability of the small intestine can reach 1.81%.
  • Test Example 15 The composition of the present invention can significantly improve the bioavailability of cosyntropin administered in the small intestine
  • composition of the present invention the weight ratio of sodium lauryl sulfate, carbomer, chitosan, and sodium citrate is 10:3:3:30.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, 1ml/kg administration volume is administered through small intestinal catheter, so that the dose of ticocotide is 200 ⁇ g/kg, another group, small intestinal catheter injection (ei) is added
  • the ticocock peptide of the composition of the present invention is 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood is collected from the tail, the blood sample is anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, Collect plasma quick-frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg ticoctide, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 16 The composition of the present invention can significantly improve the bioavailability of Octreotide administered into the small intestine
  • the weight ratio of the composition of the present invention is 21:7:6:69.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in a fasting state, administer 1ml/kg via a small intestinal catheter at a dose of 1ml/kg, so that the octreotide dose is 200 ⁇ g/kg, another group, small intestinal catheter injection (ei) plus the combination of the present invention
  • the octreotide was 200 ⁇ g/kg, and the blood was collected from the tail at 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration.
  • the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenously injected 1 ⁇ g/kg octreotide, and collect blood samples at 5, 15, 30, 60, 90, 120 min. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 17 The composition of the present invention can significantly improve the bioavailability of Mecasermin administered to the small intestine
  • the weight ratio of the composition of the present invention is 21:6:7:65.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of mecasermin is 200 ⁇ g/kg and the dose of mecasermin is 200 ⁇ g/kg in the adult SD rats with a volume of 1ml/kg.
  • Mecasermin 200 ⁇ g/kg of the composition of the present invention 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, Collect plasma quick-frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg mecasermin, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 18 The composition of the present invention can significantly improve the bioavailability of teriparatide administered to the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:65.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, 1ml/kg administration volume is administered through small intestinal catheter, so that the dose of teriparatide is 200 ⁇ g/kg, another group, small intestinal catheter injection (ei) is added
  • the teriparatide of the composition of the present invention is 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood is collected from the tail, and the blood sample is anticoagulated by 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, Collect plasma quick-frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg teriparatide, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 19 The composition of the present invention can significantly improve the bioavailability of ACTH (Corticotropin) administered into the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:65.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, administer 1ml/kg via a small intestine catheter at a dose of 1ml/kg, make ACTH dose 200 ⁇ g/kg, divide into another group, small intestine catheter injection (ei) plus the combination of the present invention
  • the ACTH of the substance was 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg ACTH, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 20 The composition of the present invention can significantly improve the bioavailability of Pramlintide administered to the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:65.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of pramlintide is 200 ⁇ g/kg and the dose of pramlintide is 200 ⁇ g/kg in adult SD rats in a fasting state.
  • Pramlintide 200 ⁇ g/kg of the composition of the invention 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and plasma was collected Quick freezing.
  • Intravenous PK test In the fasting state of animals, 1 ⁇ g/kg pramlintide was intravenously injected, and blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 21 The composition of the present invention can significantly improve the bioavailability of Vapreotide administered to the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:65.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in a fasting state, administer 1ml/kg via a small intestinal catheter at a dose of 1ml/kg, so that the dose of vaprastatide is 200 ⁇ g/kg, another group, small intestinal catheter injection (ei) supplement Vapretide 200 ⁇ g/kg of the composition of the invention, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and plasma was collected Quick freezing.
  • small intestinal catheter injection ei
  • Vapretide 200 ⁇ g/kg of the composition of the invention 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration
  • blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and plasma was collected Quick freezing.
  • Intravenous PK test In the fasting state of animals, 1 ⁇ g/kg vapratide was injected intravenously, and blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 22 The composition of the present invention can significantly improve the bioavailability of abaloparatide administered into the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:65.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in a fasting state, 1ml/kg was administered via a small intestinal catheter at a dose of 1ml/kg, so that the dose of abalotide was 200 ⁇ g/kg, divided into another group, small intestinal catheter injection (ei) added
  • the abalotide of the composition of the present invention is 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood is collected from the tail, and the blood sample is anticoagulated by 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, Collect plasma quick-frozen.
  • Intravenous PK test Animals were given an intravenous injection of 1 ⁇ g/kg abalotide in the fasting state, and blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • Test Example 23 The composition of the present invention can significantly improve the bioavailability of growth hormone (rhGH) administered to the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:65.
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in a fasting state, the dose of growth hormone is 200 ⁇ g/kg by a small intestinal catheter at a volume of 1ml/kg, and a small intestinal catheter injection (ei) adds the present invention
  • the growth hormone of the composition was 200 ⁇ g/kg, and the blood was collected from the tail at 0 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h and 3 h after administration, and the blood sample was anticoagulated with 10 mM EDTA, centrifuged at 4° C., 3000 rpm for 5 min, and the plasma was collected and snap frozen.
  • Intravenous PK test Animals in fasting state, intravenous injection of 1 ⁇ g/kg growth hormone, blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • the results showed that the growth hormone was administered 200 ⁇ g/kg through the small intestine, and the blood concentration was lower than the lower limit of ELISA detection. After adding the composition of the present invention, the bioavailability of intestinal administration can reach 0.32%.
  • Test Example 24 The composition of the present invention can significantly improve the bioavailability of Thymosin alpha1 administered into the small intestine
  • the weight ratio of the composition of the present invention is 20:6.5:6.5:65.
  • Thymus Faxin Thoroughly mix Thymus Faxin and the composition of the present invention at a weight ratio of 1:5, and set aside;
  • Test animals adult male SD rats;
  • Small intestine PK test On adult SD rats in fasting state, the dose of 1ml/kg was administered through a small intestinal catheter, the new dose of thymus method was 200 ⁇ g/kg, and the other group was divided into small intestine catheter injection (ei) supplement Thymus method of the inventive composition 200 ⁇ g/kg, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h and 3h after administration, blood was collected from the tail, the blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and plasma was collected Quick freezing.
  • Intravenous PK test The animal was in fasting state, and 1 ⁇ g/kg Thymus Faxin was injected intravenously, and blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes. The blood sample was anticoagulated with 10mM EDTA, centrifuged at 4°C, 3000rpm for 5min, and the plasma was collected and snap frozen.
  • the ELISA detection method is coated with a mouse monoclonal antibody against the target polypeptide, blocked with 1% BSA, and then incubated with a blood sample or a standard diluted with 0.1% BSA, captured by Biotin-labeled rabbit polyclonal antibody against the target polypeptide, HRP conjugated Incubate with strepavidin, and finally develop color with TMB, stop with HCl, and read at 450nm. According to the standard curve obtained from the standard, the concentration of the target polypeptide in the plasma is calculated.
  • thymus Faxin was administered 200 ⁇ g/kg through the small intestine, and the blood concentration was lower than the lower limit of ELISA detection. After adding the composition of the present invention, the bioavailability of intestinal administration can reach 0.65%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种组合物，该组合物含有：表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂；研究表明，该组合物可以促进有效成分在小肠内的吸收，提高其生物利用度。

Description

一种组合物 技术领域
本发明属于生物医药技术领域，具体涉及一种组合物，该组合物含有表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂。
背景技术
药物口服化技术一直是研究的热点。该技术涉及到将常规只能通过皮下或静脉注射的药物通过口服肠溶胶囊达到小肠后崩解，在不同制剂组合的协助下通过小肠吸收到达血液循环系统。
相比于皮下或静脉给药的药物，口服药物的优点在于两方面：就患者而言，可自我给药，药物接纳程度更高，感染的几率更低；对药物制造商而言，口服药物对车间级别要求更宽容，生产成本更低。
当然，该领域遇到的困难和瓶颈也很多，比如如何克服小肠微环境中药物不被各种消化酶降解？如何促进药物顺利通过小肠绒毛上皮细胞？如何将口服制剂的副作用降低最低？
口服药物主要通过载体转运、胞饮作用或细胞旁路等方式进入血液循环，而影响因素包括药物本身的相对分子质量、空间结构和疏水性，以及体内各种屏障(如酸屏障、酶屏障和膜屏障)，另外药物经肠胃道进入门静脉系统入肝后的首过效应，也是药物口服化的必须面对的问题。
迄今为止，在多肽类药物口服化研究领域，提高口服化药物吸收的策略主要包括，化学修饰、添加吸收促进剂、添加酶抑制剂、纳米载体、脂质体载体和微乳载体等。
发明内容
基于上述原因，申请人经过多次创造性研究，得到一种新的组合物，该组合物是由表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂制备而成的。研究表明，本发明所述的组合物具有制备成一种复合辅料，该辅料与药物有效成分组合后，可以提高该有效成分在小肠内的吸收等作用。本发明所述的组合物是一个有机的整体，通过协同作用，从而保障药物(有效成分或活性成分)在肠内的吸收。
本发明是通过下述技术方案实现的。
一种组合物，该组合物含有：表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂。
进一步地，一种药物组合物，该药物组合物含有：表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂。
其中所述表面活性剂为阴离子表面活性剂或非离子表面活性剂中一种或多种。
其中所述丙烯酸类聚合物为卡波姆、卡波姆910、丙烯酸卡波姆934、卡波姆934P中一种或多种。
其中所述甲壳素及其衍生物为甲壳素、壳聚糖、羧甲基壳聚糖、酰化壳聚糖、烷基化壳聚糖、羟基化壳聚糖、壳聚糖季铵盐、壳聚寡糖、壳聚糖硫酸酯中的一种或多种。
其中所述金属离子螯合剂为枸橼酸或及其盐、酒石酸或及其盐、苹果酸或及其盐、马来酸或及其盐、葡萄糖酸或及其盐、乙二胺四乙酸或及其盐、氨基三乙酸或及其盐、二亚乙基三胺五乙酸或及其盐中的一种或多种。
其中优选的组合物为：表面活性剂为十二烷基硫酸钠，丙烯酸类聚合物为卡波姆，甲壳素及其衍生物为壳聚糖，金属离子螯合剂为枸橼酸钠。
所述组合物用于保障药物(有效成分或活性成分)在小肠吸收。
所述组合物用于促进药物(有效成分或活性成分)在小肠内吸收。
其中所述表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物与金属离子螯合剂的重量比为：15-25:5-8:5-8:50-80。
优选地，其中所述表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物与金属离子螯合剂的重量比为：19-21:6-7:6-7:60-70。
其中所述的药物(活性成分或有效成分)包括但不限于多肽类。多肽包括Exenatide、Nesiritide、Gonadorelin、Leuprolide、Glucagon recombinant、Oxytocin、Bivalirudin、Sermorelin、Gramicidin D、Insulin recombinant、Vasopressin、Cosyntropin、Octreotide、Vapreotide、Mecasermin、Teriparatide、ACTH、Pramlintide、Abaloparatide、rhGH、thymosin alpha1等。
其中所述的药物(活性成分或有效成分)包括但不限于胰岛素及其类似物。
其中所述的药物(活性成分或有效成分)包括但不限于生长激素及其类似物。
一种促进肠吸收的组合物，该组合物由含有：表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂的原料制备而成。
上述所述的促进肠吸收的组合物，该组合物制备成辅料，该辅料用于口服制剂辅料使用。
本发明的组合物制备后，获得一种新型辅料，该辅料可以用于：不能口服只能注射的药物(有效成分或活性成分)可以通过口服给药，从而改变药物(有效成分或活性成分)的给药方式。
本发明的组合物能够保障在胃肠道内易于分解的药物(有效成分或活性成分)在肠内的吸收。
本发明的组合物能够促进在胃肠道不易于吸收的药物(有效成分或活性成分)在肠内的吸收。
由于本发明组合物是促进小肠吸收，要求在小肠内释放才能发挥其功效，因此在进行药效试验和药代试验时，啮齿类动物采用小肠导管给药，哺乳动物采用肠溶胶囊口服给药。
本发明将所述组合物和上面列举的多肽逐一搭配在啮齿类动物上进行生物利用度检测，同时会选择部分多肽在不同动物上进行药效和药代动力学的检测。
附图说明
图1为Exenatide在STZ大鼠上的PD试验；
其中：横坐标为时间(h)，纵坐标为降低血糖效率(％)；
其中：实心圆形实线为小肠注射生理盐水2ml/kg，实心方形虚线为皮下注射Exenatide 1μg/kg，实心圆形虚线为皮下注射Exenatide 250μg/kg，实心三角形虚线为皮下注射Exenatide 1mg/kg，空心三角形实线为小肠给予试验例1组合物+Exenatide(给药量Exenatide 30μg/kg)，空心圆形实线为小肠给予试验例1组合物+Exenatide(给药量Exenatide 40μg/kg)，空心方形实线为小肠给予试验例1组合物+Exenatide(给药量Exenatide 50μg/kg)，空心菱形实线为小肠给予试验例1组合物+Exenatide(给药量Exenatide 60μg/kg)。
图2为Exenatide在大鼠上的iv PK试验；
其中：横坐标为时间(min)，纵坐标为大鼠血浆中Exenatide浓度(ng/ml)。
图3为Exenatide/试验例1组合物在大鼠上的ei PK试验；
其中：横坐标为时间(min)，纵坐标为大鼠血浆中Exenatide浓度(ng/ml)。
图4为Exenatide在比格犬上的iv PK试验；
其中：横坐标为时间(min)，纵坐标为比格犬血浆中Exenatide浓度(ng/ml)。
图5为Exenatide/试验例1组合物在比格犬上的po PK试验；
其中：横坐标为时间(min)，纵坐标为比格犬血浆中Exenatide浓度(ng/ml)。
图6为Exenatide在Alloxan比格犬上的PD试验；
其中：横坐标为时间(h)，纵坐标为比格犬血糖(mM)；
其中：实心圆形实线为Alloxan比格犬餐后血糖情况，实心方形实线为Alloxan比格犬吞服Exenatide/试验例1组合物后餐后血糖情况，实心菱形实线为正常比格犬餐后血清情况。
具体实施方式
以下以具体试验例来说明本发明的技术方案，但本发明的保护范围不限于此。
本说明书试验例所述的内容仅仅是对发明构思的实现形式的列举，本发明的保护范围不应当被视为仅限于试验例所陈述的具体形式，本发明的保护范围也及于本领域技术人员根据本发明构思所能够想到的等同技术手段。尽管以下本发明的实施方案进行了描述，但本发明并不局限于上述的具体实施方案和应用领域，下述的具体实施方案仅仅是示意性的、指导性的，而不是限制性的。
本发明下述试验，是在多次创造性试验的基础上，以本发明所要保护的技术方案为基础，总结的研发人员的结论性试验。以下试验例中的定量试验，均设置三次重复实验，数据为三次重复实验的平均值或平均值±标准差。
试验例1 显著提高小肠给入Exenatide(Exendin4，EXE4)的药效
组合物为：表面活性剂为十二烷基硫酸钠，丙烯酸类聚合物为卡波姆，甲壳素及其衍生物为壳聚糖，金属离子螯合剂为枸橼酸钠，重量比为：20:6.5:6.5:65。
将Exenatide与上述组合物按照重量比1:5充分混匀，待用；
试验动物：SD雄性大鼠，腹腔注射45mg/kg STZ构建高血糖模型；
小肠药效试验：皮下注射(sc)或经小肠导管(ei)给药，于0h，3h，6h和9h采集血样检测血糖情况。
结果显示，小肠给入的Exenatide在没有添加上述组合物的情况下，其降糖效果很微弱，剂量达到1mg/kg时，其9h后的降糖效率也只有70％左右，远低于其皮下1μg/kg的剂量所能达到的50％左右。而添加本发明组合物后，给药剂量50μg/kg即可达到皮下1μg/kg的降糖效果。见附图1。
试验例2 显著提高小肠给入Exenatide的生物利用度
将Exenatide与试验例1组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Exenatide剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明试验例1组合物的Exenatide 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃3000rpm离心5min，收集血浆速冻。
为避免动物出现低血糖，在给药前，先给入1g/kg的葡萄糖。
ELISA检测方法：用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Exenatide经iv注射1μg/kg后的PK曲线的AUC为0.93ng/ml.h，经小肠注射200μg/kg，血内浓度已低于ELISA检测下限。而添加试验例1组合物后，PK曲线的AUC可以达到1.47ng/ml.h，小肠给入的生物利用度约为0.79％。试验结果见图2和图3。
试验例3 显著提高口服Exenatide的生物利用度
将Exenatide 0.7mg与试验例1组合物200mg充分混匀，并冻干，装入3号肠溶胶囊，备用；
将Exenatide 0.7mg与试验例1组合物400mg充分混匀，并冻干，装入0号肠溶胶囊，备用；
将Exenatide 0.7mg与试验例1组合物600mg充分混匀，并冻干，装入00号肠溶胶囊，备用；
将Exenatide 0.7mg与试验例1组合物200mg充分混匀，并冻干，装入3号普通胶囊，备用；
将Exenatide 0.7mg与甘露醇200mg充分混匀，并冻干，装入3号肠溶胶囊，备用；
试验动物：成年雄性比格犬。
口服PK试验：动物空腹状态，口服肠溶胶囊后，于0.5，1，1.5，2，2.5，3h采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射0.3μg/kg Exenatide，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。见图4和图5。
为避免动物出现低血糖，在给药前，先给入1g/kg的葡萄糖。
ELISA检测方法：用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
比格犬的PK数据显示，静脉注射0.3μg/kg的Exenatide的AUC约为0.82ng/ml.hour，口服Exenatide/试验例1组合物0.7mg的AUC约为1.36ng/ml.hour。口服Exenatide/试验例1组合物的生物利用度约为0.83％。
Exenatide在没有本发明组合物的协助下，无法成功进入血液内，而加入本发明组合物后，入血效率得到显著改善。虽然Exenatide的入血效率随着试验例1组合物重量的增加而略有增加，但增加的幅度有限。综合口服的便利性和药物有效性两方面的考虑，3号胶囊量比较合适。
表1 Exenatide/试验例1组合物在比格犬上的po PD试验
Figure PCTCN2020088646-appb-000001
试验例4 Exenatide/试验例1组合物可以明显抑制Alloxan比格犬餐后血糖的升高
将Exenatide 0.7mg与试验例1组合物200mg充分混匀，并冻干，装入3号肠溶胶囊，备用；
试验动物：成年雄性比格犬；
动物体检与适应：采集动物空腹血样检测血生化指标，确定一切正常后，将动物放在较安静的房间适应1周，要求每天喂食时间和喂食量保持一致；
造模前数据采集：每天采集4个时间点血样(喂食前、喂食后2h、4h、6h)，连续采集5天；
造模试验：空腹状态，静脉推注60mg/kg Alloxan溶液，一周后，每天采集4个时间点血样(喂食前、喂食后2h、4h、6h)，连续采集5天；根据采集的数据，判断模型是否合格。若合格开始药效试验；
药效试验：喂食前吞服测试胶囊，采集4个时间点血样(喂食前、喂食后2h、4h、6h)。
结果显示，Exenatide/试验例1组合物在Alloxan造模的比格犬上可以明显抑制餐后血糖的上升。见图6。
试验例5 本发明组合物显著提高小肠给入奈西利肽(Nesiritide)的生物利用度
本发明组合物：吐温80、卡波姆910、羧甲基壳聚糖与酒石酸钠的重量比为：3:1:1:10。
将Nesiritide与上述组合物按照重量比为1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Nesiritide剂量为200μg/kg，另分一组，小肠导管注射(ei)添加上述组合物的Nesiritide 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Nesiritide，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法：用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Nesiritide经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加上述组合物后，小肠给入的生物利用度可以达到1.22％。
试验例6 显著提高小肠给入戈那瑞林(Gonadorelin)的生物利用度
本发明组合物：牛磺胆酸钠、卡波姆934P、烷基化壳聚糖、马来酸钠的重量比为：17:6:6.5:55。
将Gonadorelin与上述组合物的重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Gonadorelin剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的Gonadorelin 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Gonadorelin，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Gonadorelin经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.58％。
试验例7 本发明组合物可以显著提高小肠给入亮脯利特(Leuprolide)的生物利用度
本发明组合物为：聚乙二醇4000、卡波姆、壳聚寡糖、枸橼酸的重量比为：19:6:6:60。
将Leuprolide与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Leuprolide剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的Leuprolide 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Leuprolide，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法：用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Leuprolide经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.32％。
试验例8 本发明组合物可以显著提高小肠给入替度鲁肽(Teduglutide)的生物利用度
本发明组合物：吐温80、卡波姆910、羧甲基壳聚糖与酒石酸钠的重量比为：25:8:8:80。
将Teduglutide与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Teduglutide剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的Teduglutide 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Teduglutide，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Teduglutide经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到2.13％。
试验例9 本发明组合物可以显著提高小肠给入宫缩素(Oxytocin)的生物利用度
本发明组合物为：十二烷基硫酸钠、卡波姆934、水溶性壳聚糖、乙二胺四乙酸二钠重量比为：24:7.5:7:75。
将Oxytocin与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Oxytocin剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的Oxytocin 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Oxytocin，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Oxytocin经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到2.58％。
试验例10 本发明组合物可以显著提高小肠给入比伐卢定(bivalirudin)的生物利用度
本发明组合物为：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸重量比为：19:6.5:7:67。
将Bivalirudin与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Bivalirudin剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的Bivalirudin 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Bivalirudin，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Bivalirudin经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.63％。
试验例11 本发明组合物可以显著提高小肠给入舍莫瑞林(Sermorelin)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：3:1:1:10。
将Sermorelin与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Sermorelin剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的Sermorelin 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h 和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Sermorelin，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Sermorelin经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.22％。
试验例12 本发明组合物可以显著提高小肠给入短杆菌肽D(Gramicidin)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：19:6:6:60。
将Gramicidin与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使Gramicidin剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的Gramicidin 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg Gramicidin，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，Gramicidin经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.18％。
试验例13 本发明组合物可以显著提高小肠给入重组胰岛素(rInsulin)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:68。
将rInsulin与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使rInsulin剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的rInsulin 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg rInsulin，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，rInsulin经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到0.89％。
试验例14 本发明组合物可以显著提高小肠给入加压素(Vasopressin)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：23:8:7.5:80。
将加压素与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使加压素剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的加压素200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg加压素，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，加压素经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.81％。
试验例15 本发明组合物可以显著提高小肠给入替可克肽(cosyntropin)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：10:3:3:30。
将替可克肽与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使替可克肽剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的替可克肽200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg替可克肽，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，替可克肽经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.93％。
试验例16 本发明组合物可以显著提高小肠给入奥曲肽(Octreotide)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：21:7:6:69。
将奥曲肽与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使奥曲肽剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的奥曲肽200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg奥曲肽，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，奥曲肽经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.71％。
试验例17 本发明组合物可以显著提高小肠给入美卡舍明(Mecasermin)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：21:6:7:65。
将美卡舍明与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使美卡舍明剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的美卡舍明200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg美卡舍明，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，美卡舍明经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.38％。
试验例18 本发明组合物可以显著提高小肠给入特立帕肽(teriparatide)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:65。
将特立帕肽与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使特立帕肽剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的特立帕肽200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和 3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg特立帕肽，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，特立帕肽经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到2.08％。
试验例19 本发明组合物可以显著提高小肠给入ACTH(Corticotropin)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:65。
将ACTH与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使ACTH剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的ACTH 200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg ACTH，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，ACTH经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.86％。
试验例20 本发明组合物可以显著提高小肠给入普兰林肽(Pramlintide)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:65。
将普兰林肽与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使普兰林肽剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的普兰林肽200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg普兰林肽，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，普兰林肽经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.77％。
试验例21 本发明组合物可以显著提高小肠给入伐普肽(Vapreotide)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:65。
将伐普肽与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使伐普肽剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的伐普肽200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg伐普肽，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，伐普肽经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.69％。
试验例22 本发明组合物可以显著提高小肠给入阿巴洛肽(Abaloparatide)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:65。
将阿巴洛肽与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使阿巴洛肽剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的阿巴洛肽200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg阿巴洛肽，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，阿巴洛肽经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到1.66％。
试验例23 本发明组合物可以显著提高小肠给入生长激素(rhGH)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:65。
将生长激素与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使生长激素剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的生长激素200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg生长激素，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，生长激素经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到0.32％。
试验例24 本发明组合物可以显著提高小肠给入胸腺法新(Thymosin alpha1)的生物利用度
本发明组合物：十二烷基硫酸钠、卡波姆、壳聚糖、枸橼酸钠重量比为：20:6.5:6.5:65。
将胸腺法新与本发明组合物按照重量比1:5充分混匀，待用；
试验动物：成年雄性SD大鼠；
小肠PK试验：在空腹状态的成年SD大鼠上，按1ml/kg给药体积经小肠导管给药，使胸腺法新剂量为200μg/kg，另分一组，小肠导管注射(ei)添加本发明组合物的胸腺法新200μg/kg，给药后0h，0.5h，1h，1.5h，2h，2.5h和3h，尾部采血，血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
静脉PK试验：动物空腹状态，静脉注射1μg/kg胸腺法新，于5，15，30，60，90，120min采集血样。血样经10mM EDTA抗凝，4℃、3000rpm离心5min，收集血浆速冻。
ELISA检测方法为用抗目标多肽的小鼠单抗包被，1％BSA封闭，再加入血样或0.1％BSA稀释的标准品孵育，Biotin标记的抗目标多肽的兔多抗捕获，HRP偶联的strepavidin孵育，最后TMB显色，HCl终止，450nm读数。根据标准品得到的标准曲线，计算血浆内目标多肽的浓度。
根据PK曲线计算AUC，以静脉注射(iv)的生物利用度为100％，计算小肠给药的生物利用度。
结果显示，胸腺法新经小肠给药200μg/kg，血内浓度低于ELISA检测下限。而添加本发明组合物后，小肠给入的生物利用度可以达到0.65％。
本领域的普通技术人员在本说明书的启示下和在不脱离本发明权利要求所保护的范围的情况下，还可以做出很多种的形式，这些均属于本发明保护之列。

Claims (13)

  1. 一种组合物，其含有：表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂。
  2. 根据权利要求1所述的组合物，其为药物组合物，所述药物组合物含有：表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂。
  3. 根据权利要求1或2所述的组合物，其中所述表面活性剂为阴离子表面活性剂或非离子表面活性剂中一种或多种。
  4. 根据权利要求1或2所述的组合物，其中所述丙烯酸类聚合物为卡波姆、卡波姆910、卡波姆934、卡波姆934P中一种或多种。
  5. 根据权利要求1或2所述的组合物，其中所述甲壳素及其衍生物为甲壳素、壳聚糖、羧甲基壳聚糖、酰化壳聚糖、烷基化壳聚糖、羟基化壳聚糖、壳聚糖季铵盐、壳聚寡糖、壳聚糖硫酸酯中的一种或多种。
  6. 根据权利要求1或2所述的组合物，其中所述金属离子螯合剂为枸橼酸或及其盐、酒石酸或及其盐、苹果酸或及其盐、马来酸或及其盐、葡萄糖酸或及其盐、乙二胺四乙酸或及其盐、氨基三乙酸或及其盐、二亚乙基三胺五乙酸或及其盐中的一种或多种。
  7. 根据权利要求1或2所述的组合物，其中所述表面活性剂为十二烷基硫酸钠，所述丙烯酸类聚合物为卡波姆，所述甲壳素及其衍生物为壳聚糖，所述金属离子螯合剂为枸橼酸钠。
  8. 根据权利要求1-7任一项所述的组合物，该组合物用于保障药物在小肠吸收。
  9. 根据权利要求1-7任一项所述的组合物，该组合物用于促进药物在小肠内吸收。
  10. 根据权利要求1-7任一项所述的组合物，其中所述表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物与金属离子螯合剂的重量比为：15-25:5-8:5-8:50-80。
  11. 根据权利要求1-7任一项所述的组合物，其中所述表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物与金属离子螯合剂的重量比为：19-21:6-7:6-7:60-70。
  12. 一种促进肠吸收的组合物，其特征在于该组合物由含有：表面活性剂、丙烯酸类聚合物、甲壳素及其衍生物、金属离子螯合剂的原料制备而成。
  13. 根据权利要求12所述的促进肠吸收的组合物，其特征在于该组合物制备成辅料，该辅料用于口服制剂辅料使用。
PCT/CN2020/088646 2019-06-10 2020-05-06 一种组合物 WO2020248742A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/282,833 US12036197B2 (en) 2019-06-10 2020-05-06 Composition for improving bioavailability of drugs
EP20822549.0A EP3871694A4 (en) 2019-06-10 2020-05-06 COMPOSITION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910498795.6A CN112057629A (zh) 2019-06-10 2019-06-10 一种药物组合物
CN201910498795.6 2019-06-10

Publications (1)

Publication Number Publication Date
WO2020248742A1 true WO2020248742A1 (zh) 2020-12-17

Family

ID=73658292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/088646 WO2020248742A1 (zh) 2019-06-10 2020-05-06 一种组合物

Country Status (4)

Country Link
US (1) US12036197B2 (zh)
EP (1) EP3871694A4 (zh)
CN (1) CN112057629A (zh)
WO (1) WO2020248742A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972650B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种生长抑素或其类似物的口服药物组合物
CN113509544B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
CN112972658B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种生长激素或其类似物的口服药物组合物
CN112972692A (zh) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 一种促进肠吸收的药物组合物
CN112972659A (zh) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 一种特立帕肽或阿巴洛肽的口服药物组合物
CN115137809A (zh) * 2021-03-31 2022-10-04 张菁 含有促肾上腺皮质激素及其衍生物的药物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
CN101843595A (zh) * 2009-07-16 2010-09-29 中国人民解放军第四军医大学 一种多肽、蛋白类药物口腔粘膜吸收剂型的组方及制备方法和应用
KR20170115241A (ko) * 2016-04-07 2017-10-17 가톨릭대학교 산학협력단 경구용 서방출 젤리제제 및 이의 제조방법
CN107320716A (zh) * 2017-06-27 2017-11-07 珠海亿胜生物制药有限公司 碱性成纤维细胞生长因子囊泡及其制备方法
WO2018098376A1 (en) * 2016-11-22 2018-05-31 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
CN108653233A (zh) * 2017-04-01 2018-10-16 苏州苏融生物医药有限公司 一种具有生物粘附性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
WO2007036946A1 (en) * 2005-09-28 2007-04-05 Padma Venkitachalam Devarajan Compositions for enhanced absorption of biologically active agents
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
CN101502540A (zh) * 2008-02-04 2009-08-12 北京凯瑞创新医药科技有限公司 一种以苷元为有效成分的高效药物组合物及其制备方法
CN101518554A (zh) * 2008-02-27 2009-09-02 北京凯瑞创新医药科技有限公司 一种毛冬青总苷元口服药物制剂及其制备方法和用途
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN108524866A (zh) * 2018-05-08 2018-09-14 中商华夏物产（贵州）贵和堂药业有限公司 一种中药抑菌凝胶剂及其制备方法
CN109260240A (zh) * 2018-11-22 2019-01-25 贾谊峰 一种治疗灰指甲的中药配方及蚕茧敷药装置
CN112057619A (zh) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
CN101843595A (zh) * 2009-07-16 2010-09-29 中国人民解放军第四军医大学 一种多肽、蛋白类药物口腔粘膜吸收剂型的组方及制备方法和应用
KR20170115241A (ko) * 2016-04-07 2017-10-17 가톨릭대학교 산학협력단 경구용 서방출 젤리제제 및 이의 제조방법
WO2018098376A1 (en) * 2016-11-22 2018-05-31 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
CN108653233A (zh) * 2017-04-01 2018-10-16 苏州苏融生物医药有限公司 一种具有生物粘附性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途
CN107320716A (zh) * 2017-06-27 2017-11-07 珠海亿胜生物制药有限公司 碱性成纤维细胞生长因子囊泡及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3871694A4 *

Also Published As

Publication number Publication date
CN112057629A (zh) 2020-12-11
EP3871694A1 (en) 2021-09-01
US12036197B2 (en) 2024-07-16
EP3871694A4 (en) 2022-08-31
US20210369660A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
WO2020248742A1 (zh) 一种组合物
US8084420B2 (en) Rapid acting and long acting insulin combination formulations
US20180161400A1 (en) Antidiabetic oral insulin biguanide combination
US20210008089A1 (en) Compositions and methods for treating an aggregation disease or disorder
US20080085298A1 (en) Rapid Mucosal Gel or Film Insulin Compositions
WO2009048945A1 (en) Rapid mucosal gel or film insulin compositions
US10993984B2 (en) Terlipressin compositions and their methods of use
EP1592438B1 (en) Night-time oral insulin therapy
WO2020248741A1 (zh) 一种具有降血糖作用的药物组合物
CN112057607A (zh) 一种胰高血糖素样肽-2或其类似物的口服药物组合物
CN112972692A (zh) 一种促进肠吸收的药物组合物
CN112972656B (zh) 一种胰高血糖素样肽-2或其类似物的口服药物组合物
CN112972691B (zh) 一种胰岛素或其类似物的口服药物组合物
CN113509544B (zh) 一种具有降血糖作用的药物组合物
CN112138167A (zh) 一种特立帕肽或阿巴洛肽的口服药物组合物
CN112972650B (zh) 一种生长抑素或其类似物的口服药物组合物
CN112138168B (zh) 一种胰岛素或其类似物的口服药物组合物
CN112138147B (zh) 一种胸腺法新或胸腺五肽的口服药物组合物
CN112138141B (zh) 一种生长抑素或其类似物的口服药物组合物
US20220249619A1 (en) High concentration insulin formulation
CN113058039A (zh) 一种胸腺法新或胸腺五肽的口服药物组合物
Jindal et al. Formulation and evaluation of insulin enteric microspheres for oral drug delivery
CN112972659A (zh) 一种特立帕肽或阿巴洛肽的口服药物组合物
ZA200505426B (en) Night-time oral insulin therapy
CN116635023A (zh) 用于治疗糖尿病的离子液体制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20822549

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020822549

Country of ref document: EP

Effective date: 20210524

NENP Non-entry into the national phase

Ref country code: DE